Thermo Fisher Scientific Inc. (NYSE:TMO) Holdings Decreased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,916,624 shares of the medical research company's stock after selling 56,433 shares during the quarter. Thermo Fisher Scientific accounts for about 0.7% of Price T Rowe Associates Inc. MD's portfolio, making the stock its 19th largest holding. Price T Rowe Associates Inc. MD owned about 2.85% of Thermo Fisher Scientific worth $5,679,156,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock worth $17,297,426,000 after acquiring an additional 196,864 shares during the period. Capital World Investors increased its holdings in Thermo Fisher Scientific by 1.1% in the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after acquiring an additional 104,343 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Thermo Fisher Scientific by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock valued at $4,075,540,000 after purchasing an additional 197,442 shares during the period. Norges Bank purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at about $3,149,754,000. Finally, Franklin Resources Inc. raised its stake in Thermo Fisher Scientific by 5.7% in the 3rd quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company's stock valued at $2,935,377,000 after purchasing an additional 262,062 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded down $4.17 during mid-day trading on Monday, hitting $420.07. 854,635 shares of the company's stock traded hands, compared to its average volume of 2,182,018. The firm's 50 day simple moving average is $487.28 and its 200 day simple moving average is $526.70. The company has a market cap of $158.57 billion, a PE ratio of 25.41, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 1 year low of $409.85 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. The trade was a 7.99 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,900 shares of company stock worth $13,106,062. 0.33% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Evercore ISI cut their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday. Scotiabank reduced their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research note on Friday. Barclays cut their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Citigroup decreased their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Finally, Raymond James reissued an "outperform" rating and issued a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $616.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.